1
|
Jagathesan K, Roy S. Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP). ChemMedChem 2024; 19:e202400127. [PMID: 38634306 DOI: 10.1002/cmdc.202400127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 04/15/2024] [Accepted: 04/15/2024] [Indexed: 04/19/2024]
Abstract
Hypoxia is a state characterized by low concentration of Oxygen. Hypoxic state is often found in the central region of solid tumors. Hypoxia is associated with abnormal neovascularization resulted in poor blood flow in tissues and increased proliferation of tumor cells, imbalance between O2 supply and O2 consumption in tumor cells, high concentration of proton and strong reducibility. And, these abnormalities enhance the survival potency of the hypoxic tumours and increase the resistance towards chemotherapy and radiotherapy. One of the approach for treating hypoxic region of tumour is to use reducing environment of hypoxic tumours for reducing a molecule (hypoxia activated prodrug, HAP) and as a result the active drug will be released in hypoxic region in a controlled manner from the prodrug and kill the hypoxic tumour. Co(III) and Pt(IV) complexes with monodentate active drug molecule in the axial position can be reduced to Co(II) and Pt(II) moieties and as a result, the axial ligands (active drug) could come out from the metal center and could show its anticancer activity. In this review we have highlighted the research articles where transition metal-based complexes are used as chemotherapeutic hypoxia activated prodrug molecules which are reported in last 5 years.
Collapse
Affiliation(s)
- K Jagathesan
- Dept. of Chemistry, School of Advance Sciences, Vellore Institute of Technology, Vellore, 632014, India
| | - Sovan Roy
- Dept. of Chemistry, School of Advance Sciences, Vellore Institute of Technology, Vellore, 632014, India
| |
Collapse
|
2
|
Yuan X, Xie Z, Zou T. Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment. Bioorg Chem 2024; 144:107161. [PMID: 38306826 DOI: 10.1016/j.bioorg.2024.107161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 12/28/2023] [Accepted: 01/27/2024] [Indexed: 02/04/2024]
Abstract
Hypoxia, as a prevalent feature of solid tumors, is correlated with tumorigenesis, proliferation, and invasion, playing an important role in mediating the drug resistance and affecting the cancer treatment outcomes. Due to the distinct oxygen levels between tumor and normal tissues, hypoxia-targeted therapy has attracted significant attention. The hypoxia-activated compounds mainly depend on reducible organic groups including azo, nitro, N-oxides, quinones and azide as well as some redox-active metal complex that are selectively converted into active species by the increased reduction potential under tumor hypoxia. In this review, we briefly summarized our current understanding on hypoxia-activated compounds with a particular highlight on the recently developed prodrugs and fluorescent probes for tumor treatment and diagnosis. We have also discussed the challenges and perspectives of small molecule-based hypoxia-activatable prodrug for future development.
Collapse
Affiliation(s)
- Xiaoyu Yuan
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
| | - Zhiying Xie
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
| | - Taotao Zou
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China; Guangdong Provincial Key Laboratory of Functional Supramolecular Coordination Materials and Applications, Jinan University, Guangzhou 510632, China.
| |
Collapse
|
3
|
Palmeira-Mello MV, Caballero AB, Herrera-Ramírez P, Costa AR, Santana SS, Guedes GP, Caubet A, Batista AA, Gamez P, Lanznaster M. Cobalt(III)-py 2en systems as potential carriers of β-ketoester-based ligands. J Inorg Biochem 2023; 248:112345. [PMID: 37562318 DOI: 10.1016/j.jinorgbio.2023.112345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 07/14/2023] [Accepted: 07/27/2023] [Indexed: 08/12/2023]
Abstract
Two cobalt(III) complexes containing different β-ketoesters, namely [CoIII(L1)(py2en)](ClO4)2·H2O (1) and [CoIII(L2)(py2en)](ClO4)2 (2) (py2en = N,N'-bis(pyridin-2-ylmethyl)ethylenediamine; L1- = methylacetoacetate; L2- = ethyl 4-chloroacetoacetate) have been prepared and investigated as prototypes of bioreductive prodrugs. The presence of β-ketoester and py2en ligands in 1 and 2, as well as the perchlorate counterions, was supported by IR spectroscopy and CHN elemental analysis. The composition molecular structure of both complexes was confirmed by NMR spectroscopy and ESI mass spectrometry. Structural information was also obtained for 2via X-ray diffraction analysis. The redox properties indicate that 1 and 2 are suitable for reduction under biological conditions. Investigation of DNA-interacting suggest that 1 and 2 bind DNA via electrostatic forces. Both complexes may be employed as possible platforms for the delivery of biologically active compounds, since their reaction with ascorbic acid in PBS at pH 6.2 and 7.4 at 37°C results in the release of the β-ketoester ligands upon Co(III)/Co(II) reduction.
Collapse
Affiliation(s)
- Marcos V Palmeira-Mello
- Departamento de Química, Universidade Federal de São Carlos (UFSCar), 13561-901 São Carlos, São Paulo, Brazil; Instituto de Química, Universidade Federal Fluminense, Outeiro S. João Batista S/N, 24020-141 Niterói, RJ, Brazil.; nanoBIC, Departament de Química Inorgànica i Orgànica, Secció Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain
| | - Ana B Caballero
- nanoBIC, Departament de Química Inorgànica i Orgànica, Secció Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), Universitat de Barcelona, 08028 Barcelona, Spain.
| | - Piedad Herrera-Ramírez
- nanoBIC, Departament de Química Inorgànica i Orgànica, Secció Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain
| | - Analu R Costa
- Departamento de Química, Universidade Federal de São Carlos (UFSCar), 13561-901 São Carlos, São Paulo, Brazil
| | - Savyo S Santana
- Instituto de Química, Universidade Federal Fluminense, Outeiro S. João Batista S/N, 24020-141 Niterói, RJ, Brazil
| | - Guilherme P Guedes
- Instituto de Química, Universidade Federal Fluminense, Outeiro S. João Batista S/N, 24020-141 Niterói, RJ, Brazil
| | - Amparo Caubet
- nanoBIC, Departament de Química Inorgànica i Orgànica, Secció Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain
| | - Alzir Azevedo Batista
- Departamento de Química, Universidade Federal de São Carlos (UFSCar), 13561-901 São Carlos, São Paulo, Brazil
| | - Patrick Gamez
- nanoBIC, Departament de Química Inorgànica i Orgànica, Secció Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), Universitat de Barcelona, 08028 Barcelona, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010 Barcelona, Spain
| | - Mauricio Lanznaster
- Instituto de Química, Universidade Federal Fluminense, Outeiro S. João Batista S/N, 24020-141 Niterói, RJ, Brazil..
| |
Collapse
|
4
|
Fioravanço LP, Pôrto JB, Martins FM, Siqueira JD, Iglesias BA, Rodrigues BM, Chaves OA, Back DF. A Vanadium(V) complexes derived from pyridoxal/salicylaldehyde. Interaction with CT-DNA/HSA, and molecular docking assessments. J Inorg Biochem 2023; 239:112070. [PMID: 36450221 DOI: 10.1016/j.jinorgbio.2022.112070] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 11/11/2022] [Accepted: 11/13/2022] [Indexed: 11/19/2022]
Abstract
With the increasing development of metallopharmaceuticals, coordination compounds become viable alternatives for therapeutic uses. Despite the importance of platinum derivatives in this area, first-row transition metals complexes are welcome due to their characteristics. Vanadium is a promising metal in this context, as it has a range of compounds with different biological applications, including anticancer therapeutic effects. In this effort, the study of interactions between coordination compounds with deoxyribonucleic acid and with human serum albumin is fundamental. In this way, ten iminic ligands were synthesized by condensing p-substituted aromatic benzohydrazides (OH, CH3, H, NO2, and NH2) with salicylaldehyde (L1As-L5As) or pyridoxal hydrochloride (L1P-L5P). These ligands have characteristics that allow the tridentate coordination of vanadium cations, leading to the formation of ten vanadium(V) complexes (C1As-C5As and C1P-C5P) with different structural features, all characterized by single-crystal X-ray diffraction, UV-Vis and infrared spectroscopies, and cyclic voltammetry. In addition, the complexes were tested for their interactions with calf thymus deoxyribonucleic acid and human serum albumin by spectroscopic assays and molecular docking calculations. These new results can contribute to further research and provide different ways to design new vanadium complexes with biological applications.
Collapse
Affiliation(s)
- Letícia Paiva Fioravanço
- Laboratory of Inorganic Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil
| | - Juliana Bortoluzzi Pôrto
- Laboratory of Inorganic Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil
| | - Francisco Mainardi Martins
- Laboratory of Inorganic Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil
| | - Josiéli Demetrio Siqueira
- Laboratory of Inorganic Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil
| | - Bernardo Almeida Iglesias
- Laboratory of Bioinorganic and Porphyrin Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil
| | - Bruna Matiuzzi Rodrigues
- Laboratory of Bioinorganic and Porphyrin Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil
| | - Otávio Augusto Chaves
- Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Rua Larga N°2, 3004-535, Coimbra, Portugal
| | - Davi Fernando Back
- Laboratory of Inorganic Materials, Department of Chemistry, CCNE, UFSM, Santa Maria, RS 97105-900, Brazil.
| |
Collapse
|
5
|
Structural, Theoretical Investigations, Hirshfeld Surface Analysis, and Cytotoxicity Profile of a Neocuproine-Co(II)-Based Discrete Homodinuclear Complex. Appl Biochem Biotechnol 2023; 195:871-888. [PMID: 36219332 DOI: 10.1007/s12010-022-04180-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/28/2022] [Indexed: 01/24/2023]
Abstract
In this work, we aimed to synthesize a new cobalt(II) complex, namely [Co2(μ-HIPA)(NC)2(H2O)3(NO3)]·(NO3)(C2H5OH)(1) (where H3IPA = 5-hydroxy isophthalic acid and NC = 2,9-dimethyl-1,10-phenanthroline or neocuproine), as a promising chemotherapeutic agent. The diffraction (single crystal-XRD and powder-XRD), spectroscopic (FTIR and UV-visible), molar conductance, and thermal techniques were used to characterize complex 1. Single-crystal X-ray diffraction analysis reveals that Co(II) exists in an octahedral geometry, with the ligation of four oxygen atoms, and two nitrogen atoms. Topological analysis of complex 1 reveals 2,6C6 topological type as an underlying net. The plausible intermolecular interactions within complex 1 that control the crystal packing were analyzed by Hirshfeld surface analysis. In vitro cytotoxicity of complex 1 was evaluated against acute myeloid leukemia (THP-1), colorectal (SW480), and prostate (PC-3) cancer cell lines by utilizing an MTT assay. The result shows that complex 1 can inhibit the growth of cancer cells (THP-1, SW480, and PC-3) at lower inhibitory concentration (IC50) values of > 100, 43.6, and 95.1 µM respectively. The morphological changes induced by complex 1 on THP-1 and SW480 cancer cell lines were carried out with acridine orange/ethidium bromide staining methods. Additionally, comprehensive molecular docking studies were performed to understand the potential binding interactions of complex 1 with different bio-macromolecules.
Collapse
|
6
|
Zhang J, Feng LC, Li SZ, Dong WK. Studies on two phenoxo-bridged homopolynuclear Cu(II) bis(salamo) type complexes based on theoretical calculations and fluorescence properties. Polyhedron 2022. [DOI: 10.1016/j.poly.2022.116113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
7
|
Chen YT, Zhang SN, Wang ZF, Wei QM, Zhang SH. Discovery of thirteen cobalt(II) and copper(II) salicylaldehyde Schiff base complexes that induce apoptosis and autophagy in human lung adenocarcinoma A549/DDP cells and that can overcome cisplatin resistance in vitro and in vivo. Dalton Trans 2022; 51:4068-4078. [PMID: 35179159 DOI: 10.1039/d1dt03749h] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
In this study, 13 transition metal complexes, namely, [Cu(L1H)(H2O)2]·(H2O)·NO3 (1), [Cu(LnH2)2]·(NO3)·(H2O)2 (2, n = 2; 3, n = 3; 4, n = 4; 5, n = 5), [Co(LnH)2]2·(H2O)0.5 (6, n = 2; 7, n = 3; 8, n = 4; 9, n = 5), [Cu(L6H)0.5(L10H)0.5(phen)]·(CH3OH)0.25 (10), [Cu(L11H) (phen)]4·(H2O)9 (11), [Cu(L8H)0.27(L12H)0.73(phen)]4·(H2O)5.5(CH3OH) (12), and [Cu(L9H) (phen)]3·(H2O)7·(CH3OH) (13), were synthesized using Schiff base ligands and characterized by elemental analysis (EA), infrared spectroscopy (IR), and single-crystal X-ray diffraction (SC-XRD). Compared with complexes 1-9, complexes 10-13 displayed stronger cytotoxic activities against the tested A549/DDP cancer cells (IC50 = 0.97-3.31 μM), with differences greater than one order of magnitude. Moreover, complexes 11 and 13 could induce apoptosis and autophagy in A549/DDP cells via the mitochondrial dysfunction pathway that affects the regulation of autophagy- and mitochondrial-related proteins. Importantly, the results indicate that the two novel salicylaldehyde Schiff base analogs, 11 and 13, exhibited pronounced and selective activity against A549/DDP xenografts in vivo.
Collapse
Affiliation(s)
- Ya-Ting Chen
- College of Chemistry, Guangdong University of Petrochemical Technology, Maoming, Guangdong, 525000, P R China. .,Guangxi Key Laboratory of Electrochemical and Magnetochemical Functional Materials, College of Chemistry and Bioengineering, Guilin University of Technology, Guilin, 541004, P R China
| | - Shao-Nan Zhang
- Guangxi Key Laboratory of Electrochemical and Magnetochemical Functional Materials, College of Chemistry and Bioengineering, Guilin University of Technology, Guilin, 541004, P R China
| | - Zhen-Feng Wang
- Guangxi Key Laboratory of Electrochemical and Magnetochemical Functional Materials, College of Chemistry and Bioengineering, Guilin University of Technology, Guilin, 541004, P R China
| | - Qing-Min Wei
- College of Chemistry and Food Science, Yulin Normal University, 1303 Jiaoyudong Road, Yulin 537000, PR China.
| | - Shu-Hua Zhang
- College of Chemistry, Guangdong University of Petrochemical Technology, Maoming, Guangdong, 525000, P R China. .,Guangxi Key Laboratory of Electrochemical and Magnetochemical Functional Materials, College of Chemistry and Bioengineering, Guilin University of Technology, Guilin, 541004, P R China
| |
Collapse
|
8
|
Synthesis, Spectroscopic, and Theoretical Study of Copper and Cobalt Complexes with Dacarbazine. MATERIALS 2021; 14:ma14123274. [PMID: 34199318 PMCID: PMC8231934 DOI: 10.3390/ma14123274] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 06/07/2021] [Accepted: 06/10/2021] [Indexed: 12/11/2022]
Abstract
Dacarbazine (DAC) 5-(3,3-dimethyl-1-triazenyl)imidazole-4-carboxamide is an imidazole-carboxamide derivative that is structurally related to purines. DAC belongs to the triazene compounds, which are a group of alkylating agents with antitumor and mutagenic properties. DAC is a non-cell cycle specific drug, active in all phases of the cellular cycle. In the frame of this work the 3d metal complexes (cobalt and copper) with dacarbazine were synthesized. Their spectroscopic properties by the use of FT-IR, FT-Raman, and 1HNMR were studied. The structures of dacarbazine and its complexes with copper(II) and cobalt(II) were calculated using DFT methods. The effect of metals on the electronic charge distribution of dacarbazine was discussed on the basis of calculated NBO atomic charges. The reactivity of metal complexes in relation to ligand alone was estimated on the basis of calculated energy of HOMO and LUMO orbitals. The aromaticity of the imidazole ring in dacarbazine and the complexes were compared (on the basis of calculated geometric indices of aromaticity). Thermal stability of the investigated 3d-metal complexes with dacarbazine and the products of their thermal decomposition were analyzed.
Collapse
|
9
|
Mathuber M, Gutmann M, La Franca M, Vician P, Laemmerer A, Moser P, Keppler BK, Berger W, Kowol CR. Development of a cobalt(iii)-based ponatinib prodrug system. Inorg Chem Front 2021; 8:2468-2485. [PMID: 34046181 PMCID: PMC8129988 DOI: 10.1039/d1qi00211b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 03/17/2021] [Indexed: 12/22/2022]
Abstract
Receptor tyrosine kinase inhibitors have become a central part of modern targeted cancer therapy. However, their curative potential is distinctly limited by both rapid resistance development and severe adverse effects. Consequently, tumor-specific drug activation based on prodrug designs, exploiting tumor-specific properties such as hypoxic oxygen conditions, is a feasible strategy to widen the therapeutic window. After proof-of-principal molecular docking studies, we have synthesized two cobalt(iii) complexes using a derivative of the clinically approved Abelson (ABL) kinase and fibroblast growth factor receptor (FGFR) inhibitor ponatinib. Acetylacetone (acac) or methylacetylacetone (Meacac) have been used as ancillary ligands to modulate the reduction potential. The ponatinib derivative, characterized by an ethylenediamine moiety instead of the piperazine ring, exhibited comparable cell-free target kinase inhibition potency. Hypoxia-dependent release of the ligand from the cobalt(iii) complexes was proven by changed fluorescence properties, enhanced downstream signaling inhibition and increased in vitro anticancer activity in BCR-ABL- and FGFR-driven cancer models. Respective tumor-inhibiting in vivo effects in the BCR-ABL-driven K-562 leukemia model were restricted to the cobalt(iii) complex with the higher reduction potential and confirmed in a FGFR-driven urothelial carcinoma xenograft model. Summarizing, we here present for the first time hypoxia-activatable prodrugs of the clinically approved tyrosine kinase inhibitor ponatinib and a correlation of the in vivo activity with their reduction potential.
Collapse
Affiliation(s)
- Marlene Mathuber
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Straße 42 1090 Vienna Austria
| | - Michael Gutmann
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8A 1090 Vienna Austria
| | - Mery La Franca
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8A 1090 Vienna Austria
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo via Archirafi 32 90123 Palermo Italy
| | - Petra Vician
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8A 1090 Vienna Austria
| | - Anna Laemmerer
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8A 1090 Vienna Austria
- Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna 1090 Vienna Austria
| | - Patrick Moser
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8A 1090 Vienna Austria
| | - Bernhard K Keppler
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Straße 42 1090 Vienna Austria
- Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna 1090 Vienna Austria
| | - Walter Berger
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8A 1090 Vienna Austria
- Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna 1090 Vienna Austria
| | - Christian R Kowol
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Straße 42 1090 Vienna Austria
- Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna 1090 Vienna Austria
| |
Collapse
|